Coherus BioSciences

CHRSPhase 2

Coherus BioSciences leverages its expertise in biologics development and commercialization to bring biosimilar and novel cancer therapies to market. The company has successfully launched UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar to Humira®, establishing a commercial foundation. Its strategic focus has expanded to include a promising immuno-oncology pipeline, most notably the clinical-stage anti-TIGIT antibody, toripalimab, acquired from Junshi Biosciences, positioning Coherus for future growth in the competitive oncology landscape.

Market Cap

$227.8M

Employees

300-500

Focus

Biotech

CHRS · Stock Price

USD 1.5210.91 (-87.77%)

Historical price data

AI Company Overview

Technology Platform

Integrated capabilities for the development, manufacturing, and commercialization of biosimilars and novel antibody-based immuno-oncology therapies.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
SRF617 + etrumadenant + zimberelimab	Metastatic Castration-resistant Prostate Cancer	Phase 2

Opportunities

Growth opportunities include the potential U.S.

approval and launch of toripalimab for nasopharyngeal carcinoma, expansion into larger oncology indications like NSCLC, and the clinical advancement of its internal anti-TIGIT and other novel IO candidates.

The biosimilar portfolio also offers ongoing revenue growth through market share gains.

Risk Factors

Key risks include intense pricing pressure and competition in biosimilar markets, potential regulatory setbacks for toripalimab, clinical trial failures for pipeline assets, ongoing net losses and cash burn requiring additional financing, and dependence on a limited number of key products for near-term growth.

Competitive Landscape

In biosimilars, Coherus competes with Sandoz, Viatris, and originator companies. In immuno-oncology, it faces intense competition from giants like Merck (Keytruda) and Bristol Myers Squibb (Opdivo). Differentiation is sought through niche indications (NPC for toripalimab), novel combinations, and next-generation targets like TIGIT.